Company / R&D Expense
Spyre Therapeutics, Inc. R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$171.7M
FY2025
5-year range
$57.1M / $171.7M
FY2021-FY2025
Trend
+5.4%
vs FY2024
Sector context
#93 of 210
Health Care
What the data says
At $172M, Spyre Therapeutics, Inc.'s r&d expense ranks #93 of 210 in the Health Care sector. R&D Expense has increased for 7 consecutive years, from $18M in FY2018 to $172M in FY2025.
Based on SEC 10-K filings.
$172M in FY2025 with a 5-year CAGR of +36.1%.
Improved from $90M to $172M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +42.2%
- 5-Year CAGR
- +36.1%
- 10-Year CAGR
- -
Sector benchmark
#93 of 210 in Health CareTop 44% of 210This company $171.7M Sector average $644.1M
▼
-73.4% below sector average
Key checks
Key Insights
- Spyre Therapeutics, Inc.'s r&d expense has grown for 7 consecutive years.
- 5-year CAGR of +36.1%, indicating consistent growth.
- In FY2025, r&d expense increased 5.4% year-over-year.
- Ranks #93 out of 210 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.40 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $171.7M | +5.4% |
| FY2024 | $162.8M | +81.9% |
| FY2023 | $89.5M | +50.1% |
| FY2022 | $59.6M | +4.5% |
| FY2021 | $57.1M | +55.4% |
| FY2020 | $36.7M | +60.9% |
| FY2019 | $22.8M | +25.8% |
| FY2018 | $18.1M | -20.5% |
| FY2017 | $22.8M | +25.8% |
| FY2016 | $18.1M | +58.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026